BioAge Labs, Inc.
BIOAHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioAge Labs, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The $1.01B market capitalization puts BIOA squarely in small-cap range for its industry. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Market Cap
$1.01B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-11.07
EPS (TTM)
$-2.47
EPS (Fwd)
$-2.06
ROE
-26.0%
ROA
-17.2%
Cash
$383.2M
Total Debt
$4.0M
Free CF
-$58.3M
52W Change
392.7%
Annual Financials
Cash vs Debt
BioAge Labs, Inc. holds $383.2M in cash against $4.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$58.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -26.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence BioAge Labs, Inc.'s trajectory.